- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06079879
Badanie Bomedemstatu (IMG-7289/MK-3543) w porównaniu z najlepszą dostępną terapią (BAT) u uczestników z nadpłytkowością samoistną i niewystarczającą odpowiedzią lub nietolerancją hydroksymocznika (MK-3543-006)
Randomizowane, otwarte badanie kliniczne fazy 3, kontrolowane aktywnym komparatorem, mające na celu ocenę bezpieczeństwa i skuteczności bomedemstatu (MK-3543/IMG-7289) w porównaniu z najlepszą dostępną terapią (BAT) u uczestników z nadpłytkowością samoistną, którzy mają niewystarczającą Reakcja lub nietolerancja hydroksymocznika
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Przegląd badań
Status
Warunki
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Buenos Aires
-
Pilar, Buenos Aires, Argentyna, B1629AHJ
- Hospital Universitario Austral ( Site 0104)
-
-
Buenos Aires F.D.
-
ABB, Buenos Aires F.D., Argentyna, C1199ABB
- Hospital Italiano de Buenos Aires ( Site 0105)
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentyna, T4000IKO
- C.I.C.E. 9 de Julio ( Site 1001)
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital ( Site 1100)
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital-Haematology ( Site 0501)
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital ( Site 0003)
-
Waratah, New South Wales, Australia, 2298
- Calvary Mater Newcastle ( Site 0505)
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0001)
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Health-Haematology Research ( Site 0006)
-
Melbourne, Victoria, Australia, 3021
- Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0502)
-
-
Western Australia
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital-Haematology ( Site 0504)
-
-
-
-
-
Antwerp, Belgia, 2030
- ZAS Cadix ( Site 1200)
-
-
-
-
Anhui
-
Bengbu, Anhui, Chiny, 233004
- The First Afflilated Hospital of Bengbu Medical College ( Site 3509)
-
Hefei, Anhui, Chiny, 230071
- Anhui Provincial Hospital ( Site 3513)
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chiny, 100191
- Peking University Third Hospital-Hematology ( Site 3502)
-
Beijing, Beijing Municipality, Chiny, 100730
- Peking Union Medical College Hospital ( Site 3531)
-
-
Fujian
-
Quanzhou, Fujian, Chiny, 362000
- The Second Affiliated Hospital Of Fujian Medical University ( Site 3525)
-
Xiamen, Fujian, Chiny, 361003
- The First Affiliated hospital of Xiamen University ( Site 3515)
-
-
Guangdong
-
Guangzhou, Guangdong, Chiny, 510120
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 3524)
-
Guangzhou, Guangdong, Chiny, 510515
- Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 3511)
-
-
Hebei
-
Shijiazhuang, Hebei, Chiny, 050031
- The First Hospital of Hebei Medical University ( Site 3510)
-
-
Henan
-
Zhengzhou, Henan, Chiny, 450008
- Henan Cancer Hospital-hematology department ( Site 3504)
-
-
Hubei
-
Wuhan, Hubei, Chiny, 430022
- Wuhan Union Hospital ( Site 3500)
-
-
Jiangsu
-
Nanjing, Jiangsu, Chiny, 210029
- Jiangsu Province Hospital ( Site 3507)
-
Nantong, Jiangsu, Chiny, 226001
- Affiliated Hospital of Nantong University ( Site 3527)
-
-
Jiangxi
-
Nanchang, Jiangxi, Chiny, 330209
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3505)
-
-
Jilin
-
Changchun, Jilin, Chiny, 130021
- The First Hospital of Jilin University-Hematology ( Site 3526)
-
-
Shaanxi
-
Xi'an, Shaanxi, Chiny, 710068
- Shaanxi provincial people's hospital ( Site 3516)
-
-
Shandong
-
Jinan, Shandong, Chiny, 250013
- Jinan Central Hospital ( Site 3523)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 200032
- Zhongshan Hospital,Fudan University-Hematology ( Site 3530)
-
Shanghai, Shanghai Municipality, Chiny, 200040
- Huashan Hospital, Fudan University ( Site 3529)
-
-
Sichuan
-
Chengdu, Sichuan, Chiny, 610041
- West China Hospital, Sichuan University ( Site 3518)
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chiny, 300020
- Institute of hematology&blood disease hospital ( Site 3501)
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chiny, 310003
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3508)
-
Yiwu, Zhejiang, Chiny, 322000
- Zhejiang University School of Medicine-The Fourth Affiliated Hospital ( Site 3517)
-
-
-
-
-
Paris, Francja, 75010
- Hôpital Saint-Louis-Centre d'Investigations Cliniques ( Site 0405)
-
-
Brittany Region
-
Rennes, Brittany Region, Francja, 35000
- Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 0417)
-
-
Indre-et-Loire
-
Tours, Indre-et-Loire, Francja, 37000
- Centre Hospitalier Régional Universitaire de Tours - Hôpital-Hématologie et Thérapie Cellulaire ( Site 0413)
-
-
Limousin
-
Limoges, Limousin, Francja, 87042
- Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Hématologie Clinique et Thérapie Cellu ( Site 1701)
-
-
Lorraine
-
Vandœuvre-lès-Nancy, Lorraine, Francja, 54511
- Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois-HEMATOLOGY ( Site 0407)
-
-
Nord
-
Roubaix, Nord, Francja, 59100
- Centre Hospitalier de Roubaix ( Site 1703)
-
-
Rhone
-
Pierre-Bénite, Rhone, Francja, 69310
- centre hospitalier lyon sud ( Site 0406)
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Francja, 75571
- Hôpital Saint Antoine-Service d'Hématologie et de Thérapie Cellulaire ( Site 1702)
-
-
-
-
-
Albacete, Hiszpania, 02006
- Hospital General Universitario de Albacete ( Site 0408)
-
Barcelona, Hiszpania, 08035
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0404)
-
Madrid, Hiszpania, 28041
- Hospital Universitario 12 de Octubre ( Site 2806)
-
Málaga, Hiszpania, 29010
- Hospital Universitario Virgen de la Victoria ( Site 0418)
-
Salamanca, Hiszpania, 37007
- Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 0419)
-
Valencia, Hiszpania, 46017
- Hospital Universitario Doctor Peset ( Site 0411)
-
-
Barcelona
-
Badalona, Barcelona, Hiszpania, 08916
- Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 0409)
-
L'Hospitalet Del Llobregat, Barcelona, Hiszpania, 08908
- Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 2801)
-
-
Catalonia
-
Barcelona, Catalonia, Hiszpania, 08003
- Hospital del Mar ( Site 2807)
-
Barcelona, Catalonia, Hiszpania, 08036
- HOSPITAL CLÍNIC DE BARCELONA ( Site 2800)
-
-
La Coruna
-
Santiago de Compostela, La Coruna, Hiszpania, 15706
- CHUS - Hospital Clinico Universitario ( Site 0421)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Hiszpania, 28034
- Hospital Universitario Ramón y Cajal-Hematology ( Site 2803)
-
-
Malaga
-
Marbella, Malaga, Hiszpania, 29603
- Hospital Costa del Sol-Hematology Service ( Site 0412)
-
-
-
-
-
Groningen, Holandia, 9728 NT
- Martini Ziekenhuis ( Site 2300)
-
Groningen, Holandia, 9700 RB
- University Medical Center Groningen ( Site 2304)
-
-
North Holland
-
Hoofddorp, North Holland, Holandia, 2134 TM
- Spaarne Gasthuis - Hoofddorp-Oncology ( Site 2301)
-
-
South Holland
-
Dordrecht, South Holland, Holandia, 3318 AT
- Albert Schweitzer Ziekenhuis, locatie Dordwijk-Internal Medicine ( Site 2302)
-
-
-
-
-
Hksar, Hongkong
- Queen Mary Hospital ( Site 1901)
-
-
-
-
-
Beersheba, Izrael, 8410101
- Soroka Medical Center ( Site 2100)
-
Haifa, Izrael, 3109601
- Rambam Health Care Campus ( Site 2102)
-
Haifa, Izrael, 3436212
- Carmel Hospital ( Site 0906)
-
Jerusalem, Izrael, 9112001
- Hadassah Medical Center ( Site 0904)
-
Petah Tikva, Izrael, 4941492
- Rabin Medical Center ( Site 0905)
-
Ramat Gan, Izrael, 5265601
- Sheba Medical Center ( Site 2101)
-
Tel Aviv, Izrael, 6423906
- Sourasky Medical Center ( Site 0902)
-
Tsrifin, Izrael, 7033001
- Yitzhak Shamir Medical Center. ( Site 0901)
-
-
-
-
-
Fukuoka, Japonia, 812-8582
- Kyushu University Hospital ( Site 3605)
-
Fukushima, Japonia, 960-1295
- Fukushima Medical University Hospital ( Site 3616)
-
Miyazaki, Japonia, 889-1692
- University of Miyazaki Hospital ( Site 3609)
-
Okayama, Japonia, 700-8558
- Okayama University Hospital ( Site 3604)
-
-
Aichi-ken
-
Toyoake, Aichi-ken, Japonia, 470-1192
- Fujita Health University Hospital ( Site 3613)
-
-
Chiba
-
Kashiwa, Chiba, Japonia, 277-8577
- National Cancer Center Hospital East ( Site 3610)
-
-
Ehime
-
Tōon, Ehime, Japonia, 791-0295
- Ehime University Hospital ( Site 3612)
-
-
Hokkaido
-
Sapporo, Hokkaido, Japonia, 060-8648
- Hokkaido University Hospital ( Site 3601)
-
-
Hyōgo
-
Kobe, Hyōgo, Japonia, 650-0047
- Kobe City Medical Center General Hospital ( Site 3603)
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japonia, 920-8641
- Kanazawa University Hospital ( Site 3614)
-
-
Mie-ken
-
Tsu, Mie-ken, Japonia, 514-8507
- Mie University Hospital ( Site 3615)
-
-
Miyagi
-
Sendai, Miyagi, Japonia, 983-8520
- National Hospital Organization Sendai Medical Center ( Site 3617)
-
-
Osaka
-
Hirakata, Osaka, Japonia, 573-1191
- Kansai Medical University Hospital ( Site 3607)
-
Sakai, Osaka, Japonia, 590-0197
- Kindai University Hospital ( Site 3600)
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japonia, 113-8431
- Juntendo University Hospital ( Site 3611)
-
Bunkyo-ku, Tokyo, Japonia, 113-8603
- Nippon Medical School Hospital ( Site 3608)
-
-
Yamanashi
-
Chūō, Yamanashi, Japonia, 409-3898
- University of Yamanashi Hospital ( Site 3606)
-
-
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1C 6Z8
- The Moncton Hospital-Oncology ( Site 1500)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Kolumbia, 050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 1403)
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Kolumbia, 110121
- Los Cobos Medical Center ( Site 1404)
-
-
Departamento de Córdoba
-
Montería, Departamento de Córdoba, Kolumbia, 230002
- IMAT S.A.S ( Site 1401)
-
-
-
-
-
Seoul, Korea Południowa, 02841
- Korea University Anam Hospital ( Site 0604)
-
Seoul, Korea Południowa, 05505
- Asan Medical Center ( Site 0603)
-
Seoul, Korea Południowa, 06591
- The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0606)
-
-
Kyonggi-do
-
Seongnam, Kyonggi-do, Korea Południowa, 13620
- Seoul National University Bundang Hospital-Hematology ( Site 0605)
-
-
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Niemcy, 52074
- Universitätsklinikum Aachen ( Site 1801)
-
-
Saxony
-
Dresden, Saxony, Niemcy, 01307
- Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 0402)
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Niemcy, 06120
- Universitätsklinikum Halle ( Site 0401)
-
-
-
-
-
Auckland, Nowa Zelandia, 0622
- North Shore Hospital-Department of Haematology ( Site 0051)
-
Auckland, Nowa Zelandia, 2025
- Aotearoa Clinical Trials ( Site 0050)
-
-
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polska, 40-519
- Pratia Onkologia Katowice ( Site 0702)
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Polska, 25-734
- Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 2504)
-
-
-
-
-
Braga, Portugalia, 4710-243
- Unidade Local de Saude de Braga - Hospital de Braga ( Site 0415)
-
Lisbon, Portugalia, 1449-005
- Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 2600)
-
Porto, Portugalia, 4200-072
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 0414)
-
-
-
-
Arizona
-
Glendale, Arizona, Stany Zjednoczone, 85304
- Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496)
-
-
California
-
Glendale, California, Stany Zjednoczone, 91206
- Los Angeles Cancer Network ( Site 3491)
-
Stanford, California, Stany Zjednoczone, 94305-5826
- Stanford Cancer Institute ( Site 0107)
-
Torrance, California, Stany Zjednoczone, 90502
- The Lundquist Institute ( Site 3423)
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Anschutz Medical Campus ( Site 3425)
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02111
- Tufts Medical Center ( Site 3408)
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- University of Michigan ( Site 0008)
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Hospital ( Site 3413)
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89102
- Optum Care Cancer Center ( Site 3497)
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Roswell Park Cancer Institute ( Site 3421)
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Duke University Health System (DUHS) ( Site 0016)
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400)
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Medical University of South Carolina-Hollings Cancer Center ( Site 3426)
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- University of Virginia ( Site 3422)
-
Richmond, Virginia, Stany Zjednoczone, 23219
- VCU Health Adult Outpatient Pavillion ( Site 3416)
-
-
-
-
Stockholm County
-
Huddinge, Stockholm County, Szwecja, 141 86
- Karolinska Universitetssjukhuset Huddinge ( Site 2900)
-
-
Örebro County
-
Örebro, Örebro County, Szwecja, 701 85
- Universitetssjukhuset Örebro ( Site 0403)
-
-
-
-
-
Kaohsiung City, Tajwan, 83301
- Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 3104)
-
Tainan, Tajwan, 704
- National Cheng Kung University Hospital-Clinical Trial Center ( Site 3105)
-
Taipei, Tajwan, 10048
- National Taiwan University Hospital ( Site 3101)
-
Taoyuan, Tajwan, 33305
- Chang Gung Medical Foundation-Linkou Branch ( Site 3103)
-
-
Chiayi
-
Chiayi City, Chiayi, Tajwan, 613
- Chang Gung Memorial Hospital- Chiayi ( Site 3102)
-
-
-
-
-
Ankara, Turcja (Türkiye), 06230
- Hacettepe Universite Hastaneleri-Department of Hematology ( Site 3204)
-
Ankara, Turcja (Türkiye), 06620
- Ankara UTF Cebeci Arastırma ve Uygulama Hastanesi ( Site 3210)
-
Ankara, Turcja (Türkiye), 06800
- Ankara Bilkent Şehir Hastanesi ( Site 3201)
-
Antalya, Turcja (Türkiye), 07100
- Antalya Egitim ve Arastırma Hastanesi ( Site 3207)
-
Edirne, Turcja (Türkiye), 22030
- Trakya University Medical Faculty Hospital-Hematology ( Site 3200)
-
Istanbul, Turcja (Türkiye), 34214
- Medipol Mega Universite Hastanesi-oncology ( Site 3203)
-
Kocaeli, Turcja (Türkiye), 41380
- Kocaeli Üniversitesi-Hematology ( Site 3205)
-
Mersin, Turcja (Türkiye), 33440
- VM Medical Park Mersin Hastanesi ( Site 3208)
-
Samsun, Turcja (Türkiye), 55270
- Ondokuz Mayıs Universitesi-hematology ( Site 3206)
-
-
İzmir
-
Bornova, İzmir, Turcja (Türkiye), 35100
- Ege Universitesi Hastanesi ( Site 3202)
-
-
-
-
-
Budapest, Węgry, 1088
- Semmelweis Egyetem-Belgyógyászati és Hematológiai Klinika ( Site 0708)
-
Debrecen, Węgry, 4032
- Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0707)
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Węgry
- Petz Aladar Egyetemi Oktato Korhaz ( Site 2000)
-
-
Szabolcs-Szatmár-Bereg
-
Nyíregyháza, Szabolcs-Szatmár-Bereg, Węgry, 4400
- Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór-Haematológia osztály ( Site 0706)
-
-
-
-
-
Alessandria, Włochy, 15121
- Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 0034)
-
Ancona, Włochy, 60126
- Azienda Ospedaliero Universitaria delle Marche ( Site 0302)
-
Reggio Emilia, Włochy, 42123
- Arcispedale Santa Maria Nuova ( Site 0301)
-
Torino, Włochy, 10128
- Ospedale Mauriziano ( Site 0305)
-
Varese, Włochy, 21100
- Ospedale di Circolo e Fondazione Macchi Varese ( Site 2200)
-
-
Ferrara
-
Cona, Ferrara, Włochy, 44124
- Azienda Ospedaliero Universitaria di Ferrara ( Site 0304)
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Włochy, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0308)
-
-
Lombardy
-
Milan, Lombardy, Włochy, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 2201)
-
-
Tuscany
-
Florence, Tuscany, Włochy, 50134
- Azienda Ospedaliera Universitaria Careggi ( Site 0030)
-
Pisa, Tuscany, Włochy, 56126
- Azienda Ospedaliero Universitaria Pisana-UO Ematologia UNIV ( Site 0309)
-
-
Veneto
-
Castelfranco Veneto, Veneto, Włochy, 31033
- Istituto Oncologico Veneto IRCCS-Oncoematologia ( Site 0306)
-
-
-
-
-
Manchester, Zjednoczone Królestwo, m20 4bx
- The Christie NHS Foundation Trust ( Site 3307)
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Zjednoczone Królestwo, CB2 2QQ
- Addenbrooke's Hospital ( Site 3303)
-
-
Gloucestershire
-
Gloucester, Gloucestershire, Zjednoczone Królestwo, Gl1 3NN
- Gloucestershire Royal Hospital ( Site 3302)
-
-
Great Britain
-
Lincoln, Great Britain, Zjednoczone Królestwo, LN2 5QY
- Lincoln County Hospital ( Site 3310)
-
-
Lincolnshire
-
Boston, Lincolnshire, Zjednoczone Królestwo, PE21 9QS
- Boston Pilgrim Hospital ( Site 3301)
-
-
London, City of
-
London, London, City of, Zjednoczone Królestwo, NW1 2PG
- University College London Hospital ( Site 3300)
-
London, London, City of, Zjednoczone Królestwo, SE1 9RT
- Guy's & St Thomas' NHS Foundation Trust ( Site 3305)
-
London, London, City of, Zjednoczone Królestwo, SE5 9RS
- King's College Hospital ( Site 3308)
-
-
Newport
-
Gwent, Newport, Zjednoczone Królestwo, NP20 2UB
- Royal Gwent Hospital ( Site 3304)
-
-
Windsor And Maidenhead
-
Windsor, Windsor And Maidenhead, Zjednoczone Królestwo, SL4 3HD
- GenesisCare - Windsor ( Site 3309)
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Has a diagnosis of ET per WHO 2016 diagnostic criteria for myeloproliferative neoplasms (confirmed by a central pathologist)
- Has a centrally assessed bone marrow fibrosis score of Grade 0 or Grade 1, as per a modified version of the European Consensus Criteria for Grading Myelofibrosis
- Has a history of inadequate response to or intolerance of hydroxyurea based on modified European LeukemiaNet (ELN) criteria for hydroxyurea resistance or intolerance
- Has an inadequate or loss of response to their most recent prior ET therapy, requiring a change of cytoreductive therapy
- Has a platelet count > 450 × 10^9/L (450k /μL) assessed up to 72 hours before first dose of study intervention
- Has an absolute neutrophil count (ANC) ≥0.75 × 10^9/L assessed up to 72 hours before first dose of study intervention
- Participants may have received up to 3 prior ET-directed cytoreductive agents including hydroxyurea
Exclusion Criteria:
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to bomedemstat or lysine demethylase or monoamine oxidase inhibitor (LSDi or MAOi) or the chosen best available therapy (including anagrelide, interferon alfa/pegylated interferon, ruxolitinib, or busulfan) that contraindicates participation
- History of any illness/impairment of GI function that might interfere with drug absorption (eg, chronic diarrhea or history of gastric bypass surgical procedure), confound the study results or pose an additional risk to the individual by participation in the study
- Evidence at the time of Screening of increased risk of bleeding
- History of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder
- Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Bomedemstat
Participants will begin treatment at a dose of 50 mg of bomedemstat daily. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. All participants will be treated daily for up to 52 weeks and are eligible for an extended treatment phase up to an additional 156 weeks. |
Oral Capsule
Inne nazwy:
|
|
Aktywny komparator: Best Available Therapy
Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 156 weeks at the investigator's discretion. |
Oral Tablet Oral Capsule Oral Tablet Subcutaneous Solution |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Durable Clinicohematologic Response (DCHR) Rate
Ramy czasowe: Up to approximately 52 weeks
|
DCHR rate is the percentage of participants with DCHR, defined as a confirmed reduction of platelet count to ≤400 × 10^9/L and absence of white blood cell (WBC) count elevation to >10 × 10^9/L locally assessed to be due to ET, starting by Week 24 and maintained for at least 24 weeks, and the absence of any thrombotic or major hemorrhagic events or disease progression to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) by Week 52. |
Up to approximately 52 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Clinicohematologic Response (CHR) Rate
Ramy czasowe: Up to approximately 52 weeks
|
CHR rate is the percentage of participants with CHR, defined as a confirmed reduction of platelet count to ≤400 × 10^9/L and absence of WBC count elevation to >10 × 10^9/L locally assessed to be due to ET, maintained for at least 12 weeks, and the absence of any thrombotic or major hemorrhagic events or disease progression to MF, MDS or AML by Week 52. |
Up to approximately 52 weeks
|
|
Hematologic Response (HR) Rate
Ramy czasowe: Up to approximately 52 weeks
|
HR rate is the percentage of participants with HR, HR is defined as the time from the first confirmed hematologic response to first documented evidence of confirmed platelet increase or confirmed WBC increase after latest confirmed hematologic response date. |
Up to approximately 52 weeks
|
|
Change From Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Fatigue SF-7a Total Fatigue Score
Ramy czasowe: Baseline and pre-specified timepoints through Week 52
|
The PROMIS Fatigue SF-7a is a 7-item participant-reported assessment that measures both the experience of fatigue and the interference of fatigue on daily activities over the past week. Response options are on a 5-point Likert scale, ranging from 1 = never to 5 = always. The total score is used in the analysis and is obtained by summing keyed scores of all items. Scores can range from 7 to 35, with higher scores indicating greater fatigue. |
Baseline and pre-specified timepoints through Week 52
|
|
Change From Baseline in Total Symptom Score as Measured on the MFSAF v4.0
Ramy czasowe: Baseline and pre-specified timepoints through Week 52
|
The MFSAF v4.0 is a 7-item participant-reported myelofibrosis symptom assessment which asks respondents to report symptom severity at its worst for each of the 7 items on a 0 (Absent) to 10 (Worst Imaginable) numeric rating scale. |
Baseline and pre-specified timepoints through Week 52
|
|
Duration of Durable Clinicohematologic Response (DODCHR)
Ramy czasowe: Up to approximately 52 weeks
|
For participants who demonstrate DCHR, DODCHR is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC counts until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to MF, MDS or AML. |
Up to approximately 52 weeks
|
|
Duration of Clinicohematologic Response (DOCHR)
Ramy czasowe: Up to approximately 52 weeks
|
For participants who demonstrate CHR, DOCHR is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC counts until confirmed increase of platelet and WBC count to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to MF, MDS or AML. |
Up to approximately 52 weeks
|
|
Duration of Hematologic Response (DOHR)
Ramy czasowe: Up to approximately 52 weeks
|
For participants who demonstrate HR, DOHR is defined as the time from the first confirmed hematologic response to first documented evidence of confirmed platelet increase or confirmed WBC increase after latest confirmed hematologic response date. |
Up to approximately 52 weeks
|
|
Percentage of Participants with Thrombotic Events
Ramy czasowe: Up to approximately 52 weeks
|
Thrombotic events include but are not limited to new or recurrent acute myocardial infarction, unstable angina, stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, thrombotic digital ischemia, or other thrombotic events. |
Up to approximately 52 weeks
|
|
Percentage of Participants with Major Hemorrhagic Events
Ramy czasowe: Up to approximately 52 weeks
|
Major hemorrhagic events include but are not limited to fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a decrease in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells. |
Up to approximately 52 weeks
|
|
Percentage of Participants with Disease Progression to Post-ET MF or MDS/AML
Ramy czasowe: Up to approximately 52 weeks
|
Disease progression rate is the percentage of participants with disease progression, defined as the transformation to post-ET MF, MDS, or AML as assessed by the adjudication committee. |
Up to approximately 52 weeks
|
|
Number of Participants with An Adverse Event (AE)
Ramy czasowe: Up to approximately 52 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Up to approximately 52 weeks
|
|
Number of Participants Discontinuing From Study Therapy Due to an AE
Ramy czasowe: Up to approximately 52 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Up to approximately 52 weeks
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Medical Director, Merck Sharp & Dohme LLC
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby hematologiczne
- Zaburzenia krzepnięcia krwi
- Choroby szpiku kostnego
- Zaburzenia krwotoczne
- Zaburzenia płytek krwi
- Zaburzenia mieloproliferacyjne
- Choroby hemowe i limfatyczne
- Trombocytoza
- Nadpłytkowość, niezbędna
- Związki siarki
- Organiczne chemikalia
- Węglowodory, acykliczne
- Węglowodory
- Alkan
- Alkohole
- Glikole butelenowe
- Glikole
- Mesyaty
- Alkanesulfonaty
- Kwasy alkanesulfonowe
- Kwasy sulfonowe
- Kwasy siarkowe
- Busulfan
- Ruxolitinib
- Bomedemstat
- anagrelide
Inne numery identyfikacyjne badania
- 3543-006
- IMG-7289-CTP-301 (Inny identyfikator: Imagobio)
- MK-3543-006 (Inny identyfikator: MSD)
- jRCT2031230658 (Identyfikator rejestru: Japan Registry of Clinical Trials (jRCT))
- U1111-1290-2942 (Identyfikator rejestru: UTN)
- 2023-504865-21-00 (Identyfikator rejestru: EU CT)
- 2023 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .